The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the ongoing expansion of its life sciences services, Thermo Fisher Scientific has secured a contract to develop and manufacture the experimental diabetes treatment Kapiglucagon for ImmuPharma. According to reports, Thermo Fisher was selected as the manufacturing partner for this drug candidate amid a broader assessment of the company's market valuation. This partnership is a key component of ImmuPharma's development pipeline, highlighting Thermo Fisher's role in specialized pharmaceutical production.
Analysts view Thermo Fisher (0R0H.L) as modestly undervalued due to robust demand in the life sciences sector, despite facing headwinds in the Chinese market and constraints on government spending. Per market data, the instrument's price stood at 524.49 dollars at the close of July 22, 2026, having fluctuated between a day low of 512.81 dollars and a high of 529.99 dollars during that session.
Investors are watching for sustained demand in healthcare manufacturing as a primary catalyst, particularly given the stock's current valuation metrics. At the close on July 22, 2026, the price was 524.49 dollars, and the market remains focused on how new contracts like Kapiglucagon will offset broader macroeconomic pressures and government spending volatility.